Provided by Tiger Trade Technology Pte. Ltd.

BioAtla, Inc.

3.18
0.0000
Post-market: 3.270.0855+2.69%19:30 EDT
Volume:88.74K
Turnover:286.44K
Market Cap:5.30M
PE:-0.13
High:3.41
Open:3.26
Low:3.03
Close:3.18
52wk High:71.50
52wk Low:2.81
Shares:1.67M
Float Shares:1.37M
Volume Ratio:0.99
T/O Rate:6.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-25.0700
EPS(LYR):-50.6621
ROE:-813.88%
ROA:-105.86%
PB:-0.15
PE(LYR):-0.06

Loading ...

Company Profile

Company Name:
BioAtla, Inc.
Exchange:
NASDAQ
Establishment Date:
2007
Employees:
41
Office Location:
11085 Torreyana Road,San Diego,California,United States
Zip Code:
92121
Fax:
858 558 0709
Introduction:
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and head and neck cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

Directors

Name
Position
Jay M. Short
Chairman, Chief Executive Officer and Director
Lawrence Steinman
Lead Independent Director
Edward Williams
Director
Mary Ann Gray
Director
Susan Moran
Director
Sylvia McBrinn
Director

Shareholders

Name
Position
Jay M. Short
Chairman, Chief Executive Officer and Director
Christian Vasquez
Chief Financial Officer
Eric Sievers
Chief Medical Officer